Literature DB >> 3007830

Agonist and antagonist actions of buprenorphine on three types of opioid receptor in isolated preparations.

M Kajiwara, K Aoki, K Ishii, H Numata, T Matsumiya, T Oka.   

Abstract

Both agonist and antagonist actions of buprenorphine on isolated preparations were studied. The Ke (equilibrium dissociation constant) values of both naloxone and Mr 2266 [(-)-2-(3-furylmethyl)-5, 9-diethyl-2'-hydroxy-6,7-benzomorphan] against buprenorphine and the ratio of IC50 (concentration of the drug to produce 50% inhibition of the twitch) value of buprenorphine after to before exposure of mouse vas deferens to beta-FNA (beta-fumarate methyl ester derivatives of naltrexone), an irreversible mu antagonist, suggest that buprenorphine acts as both a mu and kappa agonist on mouse vas deferens. The agonist effect of buprenorphine at relatively high doses on guinea-pig ileum and mouse vas deferens and the negative agonist effect on both rat and rabbit vas deferens indicate that buprenorphine acts as a partial agonist on isolated preparations. The Ke values of buprenorphine show that buprenorphine has about equal antagonist effectiveness against a mu and kappa agonist with approximately five-fold lower effectiveness against a delta agonist. The possible mechanisms for the several characteristic actions of buprenorphine on guinea-pig ileum such as the slow onset of action, the increased magnitude of inhibition after washing the tissue, the negative elimination of the inhibition by either washing the tissue or the naloxone administration, and the negative elimination of the antagonist action by washing the tissue were discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007830     DOI: 10.1254/jjp.40.95

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  15 in total

1.  Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.

Authors:  Michael S Virk; Seksiri Arttamangkul; William T Birdsong; John T Williams
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

2.  Compulsive-like responding for opioid analgesics in rats with extended access.

Authors:  Carrie L Wade; Leandro F Vendruscolo; Joel E Schlosburg; Daniel O Hernandez; George F Koob
Journal:  Neuropsychopharmacology       Date:  2014-07-25       Impact factor: 7.853

3.  Buprenorphine differentially alters opioid receptor adaptation in rat brain regions.

Authors:  M M Belcheva; M T Ho; E G Ignatova; L B Jefcoat; J Barg; Z Vogel; R J McHale; F E Johnson; C J Coscia
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

4.  Putative irreversible inhibitors of the human sodium-dependent bile acid transporter (hASBT; SLC10A2) support the role of transmembrane domain 7 in substrate binding/translocation.

Authors:  Pablo M González; Naissan Hussainzada; Peter W Swaan; Alexander D Mackerell; James E Polli
Journal:  Pharm Res       Date:  2012-02-22       Impact factor: 4.200

5.  A method to estimate the potency of the mu-component of an opioid having mixed mu-, and kappa- and/or delta-agonist activities.

Authors:  X F Liu; X T Fan; K Kitamura; T Taniguchi; T Oka
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

6.  Effect of thienorphine on intestinal transit and isolated guinea-pig ileum contraction.

Authors:  Pei-Lan Zhou; Yu-Lei Li; Ling-Di Yan; Zheng Yong; Gang Yu; Hua-Jin Dong; Hui Yan; Rui-Bin Su; Ze-Hui Gong
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

7.  An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Authors:  Richard C Crist; Toni-Kim Clarke; Alfonso Ang; Lisa M Ambrose-Lanci; Falk W Lohoff; Andrew J Saxon; Walter Ling; Maureen P Hillhouse; R Douglas Bruce; George Woody; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

8.  Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine.

Authors:  M M Belcheva; J Barg; R J McHale; S Dawn; M T Ho; E Ignatova; C J Coscia
Journal:  Mol Pharmacol       Date:  1993-07       Impact factor: 4.436

9.  The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference.

Authors:  Paul Marquez; Ramkumarie Baliram; Brigitte L Kieffer; Kabirullah Lutfy
Journal:  Neuropharmacology       Date:  2007-01-20       Impact factor: 5.250

10.  Evaluation of opioid-induced antinociceptive effects in anaesthetized and conscious animals.

Authors:  S J Clark; R L Follenfant; T W Smith
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.